查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1873986

抗病毒药物抗药性市场

Antiviral Drug Resistance Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

预计抗病毒药物抗药性市场将从 2024 年的 37.1 亿美元成长到 2031 年的 63.5 亿美元，2031 年至 2031 年的年复合成长率(CAGR) 为 7.9%。推动该市场成长的主要趋势包括肝病发病率上升、爱滋病毒和爱滋病的持续流行以及发展中国家对高品质产品的需求不断增长。

抗病毒药物抗药性市场分析

近年来，全球爱滋病毒/爱滋病的感染率显着上升。后天免疫缺乏症候群（爱滋病）是一种慢性且可能致命的疾病，由人类免疫缺乏病毒（HIV）引起，该病毒会严重损害免疫系统，削弱人体抵抗感染的能力。 HIV进入人体后，患者可能在一个月内出现类似流感的症状，这被称为原发性或急性HIV感染，可持续数週。根据美国卫生与公共服务部和部长少数族裔爱滋病倡议基金（SMAIF）的数据，2022年全球约有3,900万人感染HIV/爱滋病，其中有相当一部分居住在中低收入国家。例如，印度国家资讯中心发布的《2017年印度爱滋病毒感染率估计报告》估计，印度的HIV感染率为0.22%（范围在0.16%至0.30%之间）。此外，据估计，印度男性成人HIV感染率为0.25%（0.18%-0.34%），女性为0.19%（0.14%-0.25%）。因此，预计在预测期内，印度病毒感染病例的增加将推动对抗病毒药物抗药性解决方案的需求成长。

抗病毒药物抗药性市场概览

肝炎发病率的上升和爱滋病毒/爱滋病感染率的不断攀升正在推动市场成长。此外，新兴市场的扩张也可能在预测期内对需求产生正面影响。然而，替代疗法的出现可能会阻碍市场成长。近年来，美国的爱滋病毒感染率上升。美国卫生与公众服务部及美国爱滋病资讯基金会（SMAIF）的数据显示，2021年美国新增爱滋病毒感染者近3,2100人。预计这些因素将在整个预测期内推动北美抗病毒药物抗药性市场的成长。

战略洞察

抗病毒药物抗药性市场的驱动因素和机会

肝病发病率上升将有利于市场

病毒是微小的病原体，可导致多种传染病，包括流感、普通感冒和疣，以及天花、爱滋病和伊波拉等严重疾病。它们在宿主细胞内复製，并能侵入任何健康的活细胞，不断增殖产生更多病毒。不同的病毒会攻击体内特定的细胞，例如肝臟、大脑、皮肤、血液以及生殖系统、呼吸系统和消化系统等各个系统中的细胞。近年来，病毒感染，尤其是肝炎的发生率在全球范围内上升。肝炎可导致肝臟损伤和炎症，构成重大的全球健康挑战，并可能导致慢性感染，增加肝硬化和肝癌的死亡风险。肝炎分为甲型、乙型、丙型、丁型和戊型，每种类型的传播途径都不同。根据世界卫生组织（世卫组织）统计，B型肝炎的盛行率最高的地区是非洲和西太平洋地区，成人感染率分别为6.1%和6.2%。

新兴市场医疗保健投资不断成长

新兴市场，特别是亚太地区以及中南美洲，医疗保健支出不断增长，推动了聚合酶炼式反应（PCR）和新一代定序等先进技术在多种病毒性疾病治疗方案开发中的应用。美国国家癌症研究所（NCI）等机构正在资助爱滋病毒和爱滋病相关恶性肿瘤的研究，以了解慢性爱滋病毒感染者老化如何影响癌症风险、类型和生物学特征。中国、日本和巴西等国正大力投资医疗保健，以增强其市场份额，并确保医院、研究机构和诊断实验室能够有效利用医疗器材和试剂。

抗病毒药物抗药性市场細項分析

抗病毒药物抗药性市场分析按类型、疾病适应症、技术和最终用户进行细分。

  • 按类型划分，市场分为试剂盒和试剂、仪器，其中试剂盒和试剂在 2023 年占据最大的市场份额。
  • 按疾病适应症划分，市场分为 HIV、肝炎和鉅细胞病毒 (CMV)，其中 HIV 部分在 2023 年占据最大份额。
  • 从技术角度来看，市场包括免疫诊断、聚合酶炼式反应 (PCR)、次世代定序 (NGS) 等，其中免疫诊断在 2023 年将占据相当大的市场份额。
  • 按最终用户划分，市场分为医院和诊所、病理或诊断实验室以及研究机构，其中医院和诊所在 2023 年占据最大份额。

抗病毒药物抗药性市场的地理分析

抗病毒药物抗药性市场报告的地理范围分为五个区域：北美、亚太、欧洲、中东和非洲以及南美和中美洲。北美在抗病毒药物抗药性市场中占据最大份额，这主要受多种因素驱动，例如爱滋病毒和肝炎等病毒感染的流行以及政府资助的国家计画。近年来，美国的爱滋病毒感染率上升，2021年报告的新增感染病例约为32,100例。预计亚太地区在未来几年将实现最高的复合年增长率。

抗病毒药物抗药性市场报告范围

抗病毒药物抗药性市场的最新发展

抗病毒药物抗药性市场评估是基于从一手和二手研究中收集的定性和定量资料，包括重要的企业出版物、协会资料和资料库。抗病毒药物抗药性市场的主要发展包括：

  • 强生旗下杨森製药宣布，其早期临床候选药物（JNJ-1802）在《自然》杂誌上发表了最新资料，显示该药物对非人灵长类动物和小鼠具有强效的登革热防护作用。这款首创的抗病毒药物在I期临床试验中证实安全且耐受性良好，目前正推进至II期临床试验，用于登革热的预防和治疗。 （图片来源：强生公司，新闻稿，2023年3月）
  • 印度药品管理总局 (DCGI) 已授予印度西普拉有限公司 (Cipla Limited) 紧急使用授权 (EUA)，允许其在印度推出莫努匹拉韦 (Molnupiravir)，该药物将以 Cipmolnu® 为品牌名进行销售。莫努匹拉韦是第一个获得英国药品和保健产品监管局 (MHRA) 批准的口服抗病毒药物，用于治疗轻度至中度 COVID-19 患者，尤其适用于有重症风险的患者。 （图片来源：西普拉，新闻稿，2021 年 5 月）

抗病毒药物抗药性市场报告的覆盖范围和交付成果

这份题为《抗病毒药物抗药性市场规模及预测（2021-2031）》的报告对市场进行了全面分析，涵盖以下领域：

  • 全球、区域和国家层级所有关键细分市场的抗病毒药物抗药性市场规模和预测。
  • 市场趋势和动态，包括驱动因素、限制因素和主要机会。
  • 详细的PEST/波特五力模型和SWOT分析。
  • 市场分析涵盖关键趋势、全球和区域框架、主要参与者、法规和最新发展。
  • 产业格局和竞争分析，包括市场集中度、热力图分析、主要参与者以及抗病毒药物抗药性市场的最新发展。
  • 深入的公司概况。

目录

第一章：引言

第二章：全球抗病毒药物抗药性市场及主要结论

第三章：研究方法

  • 覆盖范围
  • 二手研究
  • 初步研究

第四章：全球抗病毒药物抗药性市场概况

  • 概述
  • PEST分析
    • 北美PEST分析
    • 欧洲 PEST 分析
    • 亚太地区PEST分析
    • 中东和非洲 PEST 分析
    • 南美洲和中美洲 PEST 分析
  • 专家意见
  • 按测试类型分類的测试成本
  • 按地区分類的测试量

第五章：全球抗病毒药物抗药性市场及关键产业动态

  • 主要市场驱动因素
    • 肝炎疾病发生率上升
    • 爱滋病毒/爱滋病感染率不断上升
  • 主要市场限制因素
    • 替代方案
  • 主要市场机会
    • 新兴市场医疗保健支出不断成长
  • 未来趋势
    • 对更高品质产品的需求
  • 影响分析

第六章：抗病毒药物抗药性市场及全球分析

  • 全球抗病毒药物抗药性市场收入预测与分析
  • 全球抗病毒药物抗药性市场（依地理划分）－预测与分析
  • 关键参与者的定位

第七章：全球抗病毒药物抗药性市场分析及产品细分

  • 概述
  • 2018 年及 2031 年全球抗病毒药物抗药性市场份额（按产品划分）
  • 试剂盒和试剂
  • 仪器

第八章：全球抗病毒药物抗药性市场分析及依疾病指征划分

  • 概述
  • 2018 年及 2031 年全球抗病毒药物抗药性市场份额（按疾病适应症划分）(%)
  • 爱滋病
  • 肝炎
  • 鉅细胞病毒（CMV）

第九章：全球抗病毒药物抗药性市场分析及技术分析

  • 概述
  • 2018 年及 2031 年全球抗病毒药物抗药性市场份额（按技术划分）
  • 免疫诊断
  • 聚合酶炼式反应（PCR）
  • 下一代定序（NGS）
  • 其他技术

第十章：全球抗病毒药物抗药性市场分析及最终用户划分

  • 概述
  • 2018 年及 2031 年全球抗病毒药物抗药性市场份额（按最终用户划分）(%)
  • 医院和诊所
  • 病理学和诊断实验室
  • 研究机构

第十一章：抗病毒药物抗药性市场收入及至2031年预测与地理分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
  • 中东和非洲
    • 阿联酋
    • 沙乌地阿拉伯
    • 南非
  • 南美洲和中美洲
    • 南美洲和中美洲
    • 阿根廷
    • 巴西

第十二章：抗病毒药物抗药性市场及产业概况

  • 概述

第十三章：抗病毒药物抗药性市场及主要公司概况

  • AccuBioTech Co., Ltd.
  • ACON Laboratories, Inc.
  • Siemens AG
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • Abbott
  • BD
  • F. Hoffmann-La Roche Ltd.
  • Trinity Biotech

第十四章：附录

简介目录
Product Code: TIPRE00006395

The market for antiviral drug resistance is anticipated to grow from US$ 3.71 billion in 2024 to US$ 6.35 billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.9% during the period from 2031 to 2031. Key trends driving this market include the rising incidence of liver diseases, the ongoing prevalence of HIV and AIDS, and the increasing demand for high-quality products in developing countries.

Analysis of the Antiviral Drug Resistance Market

Globally, the prevalence of HIV/AIDS has seen a significant rise in recent years. Acquired immunodeficiency syndrome (AIDS), a chronic and potentially fatal condition, is caused by the human immunodeficiency virus (HIV), which severely compromises the immune system and hinders the body's ability to combat infections. Following the entry of HIV into the body, individuals may experience flu-like symptoms within a month, known as primary or acute HIV infection, which can last for several weeks. According to the US Department of Health & Human Services and the Secretary's Minority AIDS Initiative Fund (SMAIF), approximately 39 million individuals were living with HIV/AIDS globally in 2022, with a significant proportion residing in low- and middle-income countries. For example, the India HIV Estimation 2017 report (National Informatics Centre) estimates the HIV prevalence in India at 0.22% (ranging from 0.16% to 0.30%). Furthermore, the adult HIV prevalence is estimated at 0.25% (0.18%-0.34%) among males and 0.19% (0.14%-0.25%) among females. Consequently, the rising cases of viral infections in India are expected to boost the demand for antiviral drug resistance solutions during the forecast period.

Overview of the Antiviral Drug Resistance Market

The increasing rates of hepatitis and the growing prevalence of HIV/AIDS are propelling market growth. Additionally, the expansion of emerging markets is likely to positively influence demand during the forecast period. However, market growth may be hindered by alternative treatment approaches. In the United States, the prevalence of HIV has risen in recent years. Data from the US Department of Health & Human Services and the SMAIF indicates that nearly 32,100 Americans were newly diagnosed with HIV in 2021. These factors are expected to drive the growth of the antiviral drug resistance market in North America throughout the forecast period.

Strategic Insights

Drivers and Opportunities in the Antiviral Drug Resistance Market

Increasing Incidence of Hepatic Diseases to Benefit the Market

Viruses, which are microscopic pathogens, can lead to various infectious diseases, including the flu, common cold, and warts, as well as severe conditions like smallpox, HIV/AIDS, and Ebola. They replicate within host cells and can invade any healthy living cells, multiplying and producing more viruses. Different viruses target specific cells in the body, such as those in the liver, brain, skin, blood, and various systems including reproductive, respiratory, and gastrointestinal. The incidence of viral infections, particularly hepatitis, has risen globally in recent years. Hepatitis can cause liver damage and inflammation, posing a significant global health challenge that can lead to chronic infections and increased mortality risk from cirrhosis and liver cancer. Hepatitis is classified into types A, B, C, D, and E, each with different transmission methods. According to the World Health Organization (WHO), the highest prevalence of Hepatitis B is found in the African and Western Pacific regions, with infection rates of 6.1% and 6.2% among the adult populations, respectively.

Rising Healthcare Investments in Emerging Markets

Growing healthcare expenditures in emerging markets, particularly in the Asia Pacific and South and Central America, are facilitating the development of treatment options for various viral diseases through advanced techniques such as PCR (Polymerase Chain Reaction) and next-generation sequencing. Organizations like the National Cancer Institute (NCI) are funding research on HIV and AIDS-related malignancies to understand how aging with chronic HIV infections affects cancer risk, spectrum, and biology. Countries like China, Japan, and Brazil are significantly investing in healthcare to enhance their market presence and ensure the effective use of medical instruments and reagents in hospitals, research institutes, and diagnostic laboratories.

Segmentation Analysis of the Antiviral Drug Resistance Market

The antiviral drug resistance market analysis is segmented by type, disease indication, technology, and end users.

  • By type, the market is categorized into kits and reagents, and instruments, with kits and reagents holding the largest market share in 2023.
  • By disease indication, the market is divided into HIV, hepatitis, and Cytomegalovirus (CMV), with the HIV segment commanding the largest share in 2023.
  • In terms of technology, the market includes immunodiagnostics, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, with immunodiagnostics holding a significant market share in 2023.
  • By end users, the market is segmented into hospitals and clinics, pathology or diagnostic laboratories, and research institutes, with hospitals and clinics representing the largest share in 2023.

Geographical Analysis of the Antiviral Drug Resistance Market

The geographical scope of the antiviral drug resistance market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America holds the largest market share for antiviral drug resistance, driven by factors such as the prevalence of viral infections like HIV and hepatitis, as well as government-funded national programs. The incidence of HIV in the US has risen in recent years, with approximately 32,100 new infections reported in 2021. The Asia Pacific region is expected to experience the highest CAGR in the coming years.

Scope of the Antiviral Drug Resistance Market Report

Recent Developments in the Antiviral Drug Resistance Market

The antiviral drug resistance market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Notable developments in the antiviral drug resistance market include:

  • Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of new data in the journal Nature, indicating that an early-stage clinical candidate (JNJ-1802) offers strong protection against dengue in non-human primates and mice. This first-in-class antiviral, which was found to be safe and well-tolerated in a Phase 1 clinical study, is advancing to Phase 2 clinical trials for dengue prevention and treatment. (Source: Johnson & Johnson, Press Release, March 2023)
  • Cipla Limited received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for the launch of Molnupiravir in India, which will be marketed under the brand name Cipmolnu(R). Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for treating mild-to-moderate COVID-19 in patients at high risk of severe disease. (Source: Cipla, Press Release, May 2021)

Coverage and Deliverables of the Antiviral Drug Resistance Market Report

The report titled "Antiviral Drug Resistance Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast for antiviral drug resistance at global, regional, and country levels across all key segments.
  • Market trends and dynamics, including drivers, restraints, and key opportunities.
  • Detailed PEST/Porter's Five Forces and SWOT analysis.
  • Market analysis covering key trends, global and regional frameworks, major players, regulations, and recent developments.
  • Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments in the antiviral drug resistance market.
  • In-depth company profiles.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Antiviral Drug Resistance Market and By Product
    • 1.3.2 Global Antiviral Drug Resistance Market and By Disease Indication
    • 1.3.3 Global Antiviral Drug Resistance Market and By Technology
    • 1.3.4 Global Antiviral Drug Resistance Market and By End User
    • 1.3.5 Global Antiviral Drug Resistance Market and By Geography

2. Global Antiviral Drug Resistance Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Global Antiviral Drug Resistance Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis
    • 4.2.2 Europe PEST Analysis
    • 4.2.3 Asia Pacific PEST Analysis
    • 4.2.4 Middle East and Africa PEST Analysis
    • 4.2.5 South and Central America PEST Analysis
  • 4.3 Expert Opinion
  • 4.4 Cost of Test, By Test Type
  • 4.5 Test Volume, By Region

5. Global Antiviral Drug Resistance Market and Key Industry Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Rise in the Incidences of Hepatitis Diseases
    • 5.1.2 Increasing Prevalence of HIV/AIDS
  • 5.2 Key Market Restraints
    • 5.2.1 Alternative Approaches
  • 5.3 Key Market Opportunities
    • 5.3.1 Increasing Healthcare Expenditures in Emerging Markets
  • 5.4 Future Trends
    • 5.4.1 Demand For Higher Quality Products
  • 5.5 Impact Analysis

6. Antiviral Drug Resistance Market and Global Analysis

  • 6.1 Global Antiviral Drug Resistance Market Revenue Forecasts And Analysis
  • 6.2 Global Antiviral Drug Resistance Market, By Geography - Forecasts And Analysis
  • 6.3 Positioning of Key Players

7. Global Antiviral Drug Resistance Market Analysisand by Product

  • 7.1 Overview
  • 7.2 Global Antiviral Drug Resistance Market Share by Product 2018 and 2031 (%)
  • 7.3 Kits and Reagents
    • 7.3.1 Overview
    • 7.3.2 Kits and Reagents Market Revenue and Forecast to 2031 (US$ Mn)
  • 7.4 Instruments
    • 7.4.1 Overview
    • 7.4.2 Instruments Market Revenue and Forecast to 2031 (US$ Mn)

8. Global Antiviral Drug Resistance Market Analysisand by Disease Indication

  • 8.1 Overview
  • 8.2 Global Antiviral Drug Resistance Market Share by Disease Indication 2018 and 2031 (%)
  • 8.3 HIV
    • 8.3.1 Overview
    • 8.3.2 HIV Market Revenue and Forecast to 2031 (US$ Mn)
  • 8.4 Hepatitis
    • 8.4.1 Overview
    • 8.4.2 Hepatitis Market Revenue and Forecast to 2031 (US$ Mn)
  • 8.5 Cytomegalovirus (CMV)
    • 8.5.1 Overview
    • 8.5.2 Cytomegalovirus (CMV) Market Revenue and Forecast to 2031 (US$ Mn)

9. Global Antiviral Drug Resistance Market Analysisand by Technology

  • 9.1 Overview
  • 9.2 Global Antiviral Drug Resistance Market Share by Technology 2018 and 2031 (%)
  • 9.3 Immunodiagnostics
    • 9.3.1 Overview
    • 9.3.2 Immunodiagnostics Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.4 Polymerase Chain Reaction (PCR)
    • 9.4.1 Overview
    • 9.4.2 Polymerase Chain Reaction (PCR) Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.5 Next Generation Sequencing (NGS)
    • 9.5.1 Overview
    • 9.5.2 Next Generation Sequencing (NGS) Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.6 Other Technologies
    • 9.6.1 Overview
    • 9.6.2 Other Technologies Market Revenue and Forecast to 2031 (US$ Mn)

10. Global Antiviral Drug Resistance Market Analysisand by End User

  • 10.1 Overview
  • 10.2 Global Antiviral Drug Resistance Market Share by End User 2018 and 2031 (%)
  • 10.3 Hospitals and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospitals And Clinics Market Revenue and Forecast to 2031 (US$ Mn)
  • 10.4 Pathology and Diagnostic Laboratories
    • 10.4.1 Overview
    • 10.4.2 Pathology and Diagnostic Laboratories Market Revenue and Forecast to 2031 (US$ Mn)
    • 10.4.3 List of Laboratories, By Region
  • 10.5 Research Institutes
    • 10.5.1 Overview
    • 10.5.2 Research Institutes Market Revenue and Forecast to 2031 (US$ Mn)

11. Antiviral Drug Resistance Market Revenue and Forecasts to 2031 and Geographical Analysis

  • 11.1 North America Antiviral Drug Resistance Market Revenue And Forecasts To 2031
    • 11.1.1 North America Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.1.2 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.1.3 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.1.4 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.1.5 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.1.6 North America Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.1.7 US Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.7.1 US Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.7.2 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.1.7.3 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.1.7.4 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.1.7.5 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.1.8 Canada Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.8.1 Canada Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.8.2 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.1.8.3 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.1.8.4 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.1.8.5 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.1.9 Mexico Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.9.1 Mexico Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.1.9.2 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.1.9.3 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.1.9.4 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.1.9.5 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
  • 11.2 Europe Antiviral Drug Resistance Market Revenue And Forecasts To 2031
    • 11.2.1 Europe Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.2.2 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.2.3 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.2.4 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.2.5 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.6 Europe Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.2.7 UK Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.7.1 UK Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.7.2 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.7.3 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.7.4 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.7.5 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.8 Germany Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.8.1 Germany Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.8.2 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.8.3 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.8.4 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.8.5 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.9 France Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.9.1 France Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.9.2 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.9.3 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.9.4 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.9.5 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.10 Italy Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.10.1 Italy Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.10.2 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.10.3 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.10.4 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.10.5 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.2.11 Spain Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.11.1 Spain Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.2.11.2 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.2.11.3 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.2.11.4 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.2.11.5 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
  • 11.3 Asia Pacific Antiviral Drug Resistance Market Revenue and Forecasts to 2031
    • 11.3.1 Asia Pacific Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.3.2 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.3.3 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.3.4 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.3.5 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.6 Asia Pacific Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.3.7 Japan Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.7.1 Japan Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.7.2 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.7.3 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.7.4 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.7.5 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.8 China Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.8.1 China Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.8.2 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.8.3 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.8.4 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.8.5 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.9 India Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.9.1 India Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.9.2 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.9.3 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.9.4 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.9.5 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.10 South Korea Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.10.1 South Korea Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.10.2 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.10.3 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.10.4 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.10.5 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.3.11 Australia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.11.1 Australia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.3.11.2 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.3.11.3 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.3.11.4 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.3.11.5 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
  • 11.4 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts To 2031
    • 11.4.1 Middle East and Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.4.2 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.4.3 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.4.4 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.4.5 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.4.6 Middle East and Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.4.7 UAE Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.7.1 UAE Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.7.2 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.4.7.3 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.4.7.4 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.4.7.5 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.4.8 Saudi Arabia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.8.1 Saudi Arabia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.8.2 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.4.8.3 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.4.8.4 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.4.8.5 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.4.9 South Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.9.1 South Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.4.9.2 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.4.9.3 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.4.9.4 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.4.9.5 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
  • 11.5 South And Central America Antiviral Drug Resistance Market Revenue And Forecasts To 2031
    • 11.5.1 South and Central America Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
    • 11.5.2 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
    • 11.5.3 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
    • 11.5.4 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
    • 11.5.5 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.5.6 South and Central America Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
    • 11.5.7 Argentina Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.5.7.1 Argentina Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.5.7.2 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.5.7.3 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.5.7.4 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.5.7.5 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
    • 11.5.8 Brazil Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.5.8.1 Brazil Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
      • 11.5.8.2 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
      • 11.5.8.3 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
      • 11.5.8.4 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
      • 11.5.8.5 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)

12. Antiviral Drug Resistance Marketand Industry Landscape

  • 12.1 Overview

13. Antiviral Drug Resistance MarketandKey Company Profiles

  • 13.1 AccuBioTech Co., Ltd.
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Financial Overview
    • 13.1.4 Product Portfolio
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 ACON Laboratories, Inc.
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Financial Overview
    • 13.2.4 Product Portfolio
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Siemens AG
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Financial Overview
    • 13.3.4 Product Portfolio
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 bioMerieux SA
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Financial Information
    • 13.4.4 Product Portfolio
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Bio-Rad Laboratories, Inc.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Financial Information
    • 13.5.4 Product Portfolio
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Danaher
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Financial Overview
    • 13.6.4 Product Portfolio
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Abbott
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Financial Overview
    • 13.7.4 Product Portfolio
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 BD
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Financial Overview
    • 13.8.4 Product Portfolio
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 F. Hoffmann-La Roche Ltd.
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Financial Overview
    • 13.9.4 Product Portfolio
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Trinity Biotech
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Financial Overview
    • 13.10.4 Product Portfolio
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms